Medindia

X

Reportlinker Adds The Global Market for AIDS/HIV Testing and Treatment

Thursday, May 12, 2011 General News J E 4
Advertisement

NEW YORK, May 12, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Global Market for AIDS/HIV Testing and Treatment

http://www.reportlinker.com/p0492942/The-Global-Market-for-AIDS/HIV-Testing-and-Treatment.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

REPORT HIGHLIGHTS

* The global HIV/AIDS market, including branded products and generics, was valued at $11.3 billion in 2010. This market is expected to reach $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 forecast period to reach $14.1 billion in 2016.

* Branded products to treat HIV/AIDS were worth nearly $10.7 billion in 2010 and should reach $11 billion in 2011. This sector is expected to reach $13.2 billion in 2016, a compound annual growth rate (CAGR) of 4.6%.

* The market needs in the developing world are met by a number of generic suppliers. This sector is estimated to reach $690 million in 2011 and is expected to increase at a 4.4% compound annual growth rate (CAGR) to reach $830 million in 2016.

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the management of HIV infection and AIDS. Important trends are identified and sales' forecasts by product categories and major country markets are provided through 2016; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the HIV/AIDS market. The wider economic environment is also taken into account.

REASONS FOR DOING THE STUDY

HIV/AIDS is one of the most catastrophic threats to human health throughout the world. Advanced treatment options and improved methods of diagnosis have helped to moderate the growth of the epidemic and this has presented opportunities for companies prepared to engage actively in this field. However, the management of HIV/AIDS is still, in many respects, an unfulfilled market and there is an ongoing urgent need for promising new research directions as well as optimal exploitation of the treatment and diagnostic options already developed. In this dynamic and continually evolving marketplace, there is a need for an up-to-date, comprehensive appraisal covering both strategic and tactical options confronting the pharmaceutical industry.

SCOPE OF REPORT

This report summarizes knowledge of HIV/AIDS and discusses the present status and evolution of the global AIDS epidemic, with analyses by selected major national markets. Latest treatment and diagnostic options and practices are described and their cost implications clarified, especially in the context of treatment affordability in countries of widely varying economic status. The emergence of a considerable generic medicine component in the marketplace, alongside the presence of original branded medicines, is discussed; profiles of both originator companies and generic suppliers are included and the role of governmental and charitable agencies explained. The current market for AIDS therapies is analyzed with breakdowns by major country and 5-year forecasts. Finally, major ongoing research is summarized and promising directions identified.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected at 2011 dollar value without attempting to predict the effect of inflation/deflation.

National MARKET ANALYSES AND FORECASTS are provided for seven economically advanced countries and for five countries classified as of low to medium economic advancement.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Primary research included interviews with leading individuals in pharmaceutical companies and industry associations. Primary sources of published data included company annual reports, SEC filings, and government and industry publications. Secondary sources consisted of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts were pooled from a range of sources and critically assessed by BCC.

INTENDED AUDIENCE

This report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.

INFORMATION SOURCES

Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant trade associations such as Pharmaceutical Journal and AIDS Research and Therapy.

ANALYST CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the HIV/AIDS marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 1

MARKET ANALYSES AND FORECASTS 2

INTENDED AUDIENCE 2

INFORMATION SOURCES 2

ANALYST CREDENTIALS 2

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER TWO: SUMMARY 4

HIV/AIDS 4

ECONOMIC REALITIES 4

PHARMACEUTICAL SUPPLIERS 5

SUMMARY TABLE ARV MARKET ESTIMATES AND FORECASTS,

THROUGH 2016 ($ MILLIONS) 5

SUMMARY FIGURE ARV MARKET ESTIMATES AND FORECASTS,

2010-2016 ($ MILLIONS) 6

CHAPTER THREE: OVERVIEW: BRIEFING ON HIV AND AIDS 7

ORIGINS OF HIV 7

THE VIRUS 8

SUBTYPES OF HIV-1 9

THE STRUCTURE OF HIV 9

NINE GENES 9

VIRAL LIFE-CYCLE 10

REVERSE TRANSCRIPTION AND INTEGRATION 10

TRANSCRIPTION AND TRANSLATION 10

FROM HIV TO AIDS 11

TABLE 1 RELATIONSHIP BETWEEN VIRAL LOAD AND AIDS RISK 12

DIAGNOSIS 12

DIAGNOSIS (CONTINUED) 13

TREATMENT 14

TREATMENT (CONTINUED) 15

DISEASE PROGRESSION 16

SYMPTOMS AND SIGNS 16

A NOTE ON TRANSMISSION 17

A NOTE ON TRANSMISSION (CONTINUED) 18

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC 19

TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS 19

TABLE 2 (CONTINUED) 20

REGIONAL OVERVIEW 20

SUB-SAHARAN AFRICA 21

ASIA 21

CARIBBEAN 22

EASTERN EUROPE AND CENTRAL ASIA 22

NORTH AFRICA AND THE MIDDLE EAST 22

CENTRAL AND SOUTH AMERICA 22

NORTH AMERICA, OCEANIA AND WESTERN AND

CENTRAL EUROPE 23

FIGURE 1 DISTRIBUTION OF HIV BY REGION, 2009 24

CHAPTER FIVE: CURRENT TREATMENT AND PIPELINE 25

CURRENT ARV DRUGS 25

TABLE 3 APPROVED ANTI-HIV DRUGS 26

CHOOSING THE COMBINATION 27

FIRST- AND SECOND-LINE THERAPY 27

RECENTLY APPROVED DRUGS AND THE RESEARCH PIPELINE 28

ENTRY INHIBITORS 28

INTEGRASE INHIBITORS 29

MATURATION INHIBITORS 29

NNRTIS 29

NRTI 30

NRTI (Continued) 31

AN INTRIGUING POSSIBILITY 32

BUT A MYSTERY REMAINS 32

But a Mystery Remains (Continued) 33

CHAPTER SIX: GLOBAL AND NATIONAL MARKETS 34

EVOLUTION OF THE MARKET 34

THE GLOBAL FUND 34

ENTER THE GENERICS 35

FIGURE 2 EFFECT OF GENERIC COMPETITION ON ARV BRAND

PRICES 36

WHAT PRICE PATENTS? 36

AVOIDING CONFRONTATION WITH PHARMA MAJORS 37

Tiered Pricing 38

Voluntary and Compulsory Licensing 39

MARKET ESTIMATES AND FORECASTS 39

THE HIV/AIDS MARKET BY REGIONS AND COUNTRIES 40

NORTH AMERICA 40

United States 40

United States (Continued) 41

Current Status 42

FIGURE 3 DISTRIBUTION OF AIDS CASES ACROSS THE US 43

TABLE 4 CURRENT AND FORECAST ARV MARKET IN THE US,

THROUGH 2016 ($000) 44

LATIN AMERICA 44

Latin America (Continued) 45

Brazil 46

Current Status 46

TABLE 5 CURRENT AND FORECAST ARV MARKET IN BRAZIL,

THROUGH 2016 ($000) 47

Argentina 47

TABLE 6 CURRENT AND FORECAST ARV MARKET IN ARGENTINA,

THROUGH 2016 ($000) 48

Mexico 48

TABLE 7 CURRENT AND FORECAST ARV MARKET IN MEXICO,

THROUGH 2016 ($000) 49

SOURCE: BCC RESEARCH 49

ASIA 49

Japan 50

TABLE 8 CURRENT AND FORECAST ARV MARKET IN JAPAN,

THROUGH 2016 ($000) 51

Source: BCC Research 51

Republic of Korea 51

TABLE 9 CURRENT AND FORECAST ARV MARKET IN REPUBLIC

OF KOREA, THROUGH 2016 ($000) 52

India 52

Distribution 53

Andhra Pradesh 53

Goa 54

Karnataka 54

Maharashtra 54

Tamil Nadu 54

Manipur 54

ARV Availability 55

TABLE 10 CURRENT AND FORECAST ARV MARKET IN INDIA,

THROUGH 2016 ($000) 56

China 56

FIGURE 4 REGIONAL DISTRIBUTION OF HIV IN CHINA 57

Treatment 58

Current Situation 58

TABLE 11 CURRENT AND FORECAST ARV MARKET IN CHINA,

THROUGH 2016 ($000) 59

Thailand 59

TABLE 12 CURRENT AND FORECAST ARV MARKET IN THAILAND,

THROUGH 2016 ($000) 60

EUROPE 61

FIGURE 5 HIV RATES ACROSS EUROPE 61

Germany 62

Challenges 63

TABLE 13 CURRENT AND FORECAST ARV MARKET IN GERMANY,

THROUGH 2016 ($000) 64

France 64

TABLE 14 CURRENT AND FORECAST ARV MARKET IN FRANCE,

THROUGH 2016 ($000) 65

Italy 65

TABLE 15 CURRENT AND FORECAST ARV MARKET IN ITALY,

THROUGH 2016 ($000) 66

United Kingdom 66

TABLE 16 CURRENT AND FORECAST ARV MARKET IN UK,

THROUGH 2016 ($000) 67

Spain 67

TABLE 17 CURRENT AND FORECAST ARV MARKET IN SPAIN,

THROUGH 2016 ($000) 68

CENTRAL AND EASTERN EUROPE 69

Czech Republic 69

TABLE 18 CURRENT AND FORECAST ARV MARKET IN CZECH

REPUBLIC, THROUGH 2016 ($000) 70

Poland 70

TABLE 19 CURRENT AND FORECAST ARV MARKET IN POLAND,

THROUGH 2016 ($000) 71

Hungary 72

TABLE 20 CURRENT AND FORECAST ARV MARKET IN HUNGARY,

THROUGH 2016 ($000) 72

Russian Federation 72

Russian Federation (Continued) 73

TABLE 21 CURRENT AND FORECAST ARV MARKET IN RUSSIA,

THOUGH 2016 ($000) 74

AFRICA 74

South Africa 74

TABLE 22 CURRENT AND FORECAST ARV MARKET IN SOUTH

AFRICA, THROUGH 2016 ($000) 75

CHAPTER SEVEN: MARKET ANALYSIS BY PRODUCTS AND

COMPANIES 76

PRODUCTS 76

TABLE 23 PRODUCT PROFILE: RETROVIR 76

TABLE 24 PRODUCT PROFILE: VIRAMUNE 77

TABLE 25 PRODUCT PROFILE: ZERIT 78

TABLE 26 PRODUCT PROFILE: EPIVIR 78

TABLE 27 PRODUCT PROFILE: INVIRASE 79

TABLE 28 PRODUCT PROFILE: NORVIR 80

TABLE 29 PRODUCT PROFILE: CRIXIVAN 81

TABLE 30 PRODUCT PROFILE: VIRACEPT 81

TABLE 31 PRODUCT PROFILE: RESCRIPTOR 82

TABLE 32 PRODUCT PROFILE: SUSTIVA 83

TABLE 33 PRODUCT PROFILE: ZIAGEN 84

TABLE 34 PRODUCT PROFILE: VIDEX 84

TABLE 35 PRODUCT PROFILE: VIREAD 85

TABLE 36 PRODUCT PROFILE: FUZEON 86

TABLE 37 PRODUCT PROFILE: REYATAZ 86

TABLE 38 PRODUCT PROFILE: EMTRIVA 87

TABLE 39 PRODUCT PROFILE: LEXIVA 88

TABLE 40 PRODUCT PROFILE: APTIVUS 88

TABLE 41 PRODUCT PROFILE: PREZISTA 89

TABLE 42 PRODUCT PROFILE: SELZENTRY 89

TABLE 43 PRODUCT PROFILE: ISENTRESS 90

TABLE 44 PRODUCT PROFILE: INTELENCE 91

COMBINATION ANTIVIRALS 91

TABLE 45 PRODUCT PROFILES: ANTIVIRAL COMBINATIONS 92

MARKET PENETRATION BY PRODUCT 92

TABLE 46 SALES OF ANTIRETROVIRAL PRODUCTS, 2008-2010 ($

MILLIONS, % CHANGE) 93

TABLE 47 FIRST PATENT EXPIRIES ON ARV PRODUCTS, 2011-2016 94

TABLE 48 MARKET FOR ARV PRODUCTS, THROUGH 2016 ($

MILLIONS) 95

MARKET SHARE BY COMPANY 95

FIGURE 6 ARV COMPANY SHARES, 2010 (%) 96

THE GENERIC SECTOR 96

The Generic Sector (Continued) 97

CHAPTER EIGHT: COMPANY PROFILES 98

MAJOR PHARMACEUTICAL COMPANIES 98

ABBOTT LABORATORIES 98

BOEHRINGER INGELHEIM GMBH 99

BRISTOL-MYERS SQUIBB 100

GILEAD SCIENCES INC 101

GLAXOSMITHKLINE PLC 102

MERCK & CO INC 103

PFIZER INC 104

TIBOTEC BABE 105

VIIV HEALTHCARE 106

THE GENERICS SECTOR 107

AJANTA PHARMA (MAURITIUS) LIMITED 107

CIPLA LTD 108

THE GOVERNMENT PHARMACEUTICAL ORGANIZATION 109

HETERO DRUGS LTD 110

KOREA UNITED PHARMACEUTICALS INC 111

LABORATORIOS RICHMOND SA 111

MEDOPHARM 112

RANBAXY LABORATORIES LIMITED 113

SRS PHARMACEUTICALS 114

STRIDES ARCOLAB 115

TABLE 49 STRIDES ARV PRODUCTS 115

TABLE 49 (CONTINUED) 116

VAISHNAVI LIFESCIENCE PVT LTD 116

CHAPTER NINE: VACCINE DEVELOPMENTS 117

VAXGEN 117

CELL-MEDIATED IMMUNITY 118

MERCK CANDIDATE 118

THAILAND STUDY 119

REASONS FOR OPTIMISM? 120

GEOVAX CANDIDATE 120

BIO-NOR CANDIDATE 120

FIT BIOTECH APPROACH 121

TIME IS NOT ON OUR SIDE 122

TIME IS NOT ON OUR SIDE (CONTINUED) 123

CHAPTER TEN: HIV TESTING: BACKGROUND AND MARKET 124

ANTIBODY TESTS 124

ELISA 124

WESTERN BLOT 124

INTERPRETING ANTIBODY TESTS 125

OTHER TESTS 126

P24 ANTIGEN TEST 126

NUCLEIC ACID BASED TESTS (NAT) 126

CD4 TEST 127

HOME TESTING 128

Home Access Express HIV-1 Test 128

OraQuick 129

Orasure 129

Uni-Gold 129

Clearview Complete HIV 1/2 and Clearview HIV 1/2 Stat-

Pak 129

INSTI HIV-1/HIV-2* Rapid Antibody Test 129

Reveal HIV 129

TABLE 50 COMPARISON OF HIV HOME SAMPLING AND HOME

TESTING SERVICES 130

THE TESTING MARKET 130

TABLE 51 RAPID HIV TEST PRODUCTS 131

TABLE 51 (CONTINUED) 132

TABLE 52 HIV TESTING MARKET FORECAST, THROUGH 2016 ($

MILLIONS) 133

TABLE 53 REGIONAL SHARES OF HIV TESTING MARKET,

THROUGH 2016 ($ MILLIONS) 133

COMPANIES INVOLVED IN HIV TESTING 134

ABBOTT DIAGNOSTICS 134

BIOMÉRIEUX SA 135

Prevention/Diagnosis 135

Monitoring 136

BIO-RAD LABORATORIES INC 136

CALYPTE BIOMEDICAL CORPORATION 137

CELERA GROUP 137

GEN-PROBE INC 138

INNOGENETICS NV 139

INVERNESS MEDICAL PROFESSIONAL DIAGNOSTICS 140

MEDMIRA LABORATORIES INC 140

ORASURE TECHNOLOGIES INC 141

ORTHO-CLINICAL DIAGNOSTICS INC 142

ROCHE DIAGNOSTICS 143

SIEMENS HEALTHCARE DIAGNOSTICS INC 144

APPENDIX ONE: GLOSSARY 145

APPENDIX ONE 145

APPENDIX ONE (CONTINUED) 146

APPENDIX ONE (CONTINUED) 147

APPENDIX TWO: THE HUMAN IMMUNE SYSTEM 148

APPENDIX TWO 148

LYMPHOCYTES 149

KILLER AND HELPER T CELLS 149

IMMUNODEFICIENCY 150

APPENDIX THREE: VIRUSES 151

APPENDIX THREE 151

DNA VIRUSES 152

RNA VIRUSES 152

REVERSE TRANSCRIBING VIRUSES 153

HOST DEFENSE MECHANISMS 153

PREVENTION AND TREATMENT 154

To order this report:

Pathology Industry: The Global Market for AIDS/HIV Testing and Treatment

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cord Blood America Reduces "Afford-A-Cord" Program...
S
Banner Sun Health Research Institute Researchers F...